



Fortis Healthcare Limited

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

FHL/SEC/2023-24

February 23, 2024

The National Stock Exchange of India Ltd.
Scrip Symbol: FORTIS

BSE Limited
Scrip Code:532843

Sub.: Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations).

Dear Sir/ Ma'am,


In terms of Regulation 30(4) of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and reference to our letter dated November 14, 2023 and December 26, 2023 regarding a material litigation filed by Northern TK Venture Pte Ltd., the Promoter shareholder of the Company ("NTK"), against Daiichi Sankyo Company, Limited before the Tokyo District Court in Japan.

In furtherance to the aforesaid announcements, a copy of the announcement released by IHH Parent Company of NTK, to the Bursa, Malaysia and Singapore Stock Exchanges is enclosed herewith.

We will inform you in case of any material developments on the above matter.

This is for your information and records.

Thanking you,
Yours sincerely,
For **Fortis Healthcare Limited**


Vivek Kumar Goyal
Chief Financial Officer
Encl. as above



FORTIS HEALTHCARE LIMITED

Regd. Office : Fortis Hospital, Sector 62, Phase – VII, Mohali – 160062
Tel : 0172-5096001. Fax : 0172-5096221. CIN : L85110PB1996PLC045933



IHH Healthcare

Registration No. 201001018208 (901914-V)
(Incorporated in Malaysia)

IHH HEALTHCARE BERHAD (“IHH” OR THE “COMPANY”)

Type : General Announcement
Subject : Material Litigation
Description : Claim before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd against Daiichi Sankyo Company, Limited

IHH HEALTHCARE BERHAD (“IHH” OR THE “COMPANY”)

1. **SUBSCRIPTION OF 235,294,117 NEW EQUITY SHARES OF FACE VALUE OF INDIAN RUPEES (“INR”) 10 EACH (“FORTIS SHARES”) IN FORTIS HEALTHCARE LIMITED (“FORTIS”) THROUGH PREFERENTIAL ALLOTMENT BY FORTIS TO AN INDIRECT WHOLLY-OWNED SUBSIDIARY OF IHH, NORTHERN TK VENTURE PTE LTD (“NTK” OR THE “ACQUIRER”) (“SUBSCRIPTION”);**
2. **MANDATORY OPEN OFFER FOR ACQUISITION OF UP TO 197,025,660 FORTIS SHARES REPRESENTING ADDITIONAL 26.10% OF THE EXPANDED VOTING SHARE CAPITAL OF FORTIS BY THE ACQUIRER (“FORTIS OPEN OFFER”); AND**
3. **MANDATORY OPEN OFFER FOR ACQUISITION OF UP TO 4,894,308 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF INR 10 EACH (“MALAR SHARES”), REPRESENTING 26.11% OF THE FULLY DILUTED VOTING EQUITY SHARE CAPITAL OF FORTIS MALAR HOSPITALS LIMITED (“MALAR”) BY THE ACQUIRER (“MALAR OPEN OFFER”, AND COLLECTIVELY WITH THE FORTIS OPEN OFFER, THE “OPEN OFFERS”).**

[THE SUBSCRIPTION, FORTIS OPEN OFFER, AND THE MALAR OPEN OFFER ARE HEREINAFTER COLLECTIVELY REFERRED AS THE “TRANSACTION”]

We refer to our earlier announcements dated 13 July 2018, 15 August 2018, 13 November 2018, 17 December 2018, 18 November 2019, 3 February 2020, 5 March 2020, 17 March 2020, 14 August 2020, 22 September 2022, 23 September 2022, 26 September 2022, 11 November 2022, 17 November 2022, 14 November 2023, 24 November 2023 and 26 December 2023 (“**Said Announcements**”) in relation to the Transaction. Unless otherwise expressed or defined herein, all capitalised terms used in this announcement shall have the same meanings as ascribed to them in the Said Announcements (or any of them).



IHH Healthcare

The Board of Directors of IHH wishes to announce that, on 9 February 2024, NTK, an indirect wholly-owned subsidiary of IHH, has submitted the following two briefs to the Court:

- (1) a brief which sets out a substantive exposition of facts and applicable laws; and
- (2) a brief on the jurisdiction of the Japanese court for this case.

The parties attended the second hearing on 22 February 2024 before the Court, where NTK's filings were presented to the Court. The next hearing before the Court is scheduled for 14 May 2024.

The Company will make further announcements in the event of any material developments on the above matter.

This announcement is dated 22 February 2024.